Overview

Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU)

Status:
NOT_YET_RECRUITING

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to study patients with chronic spontaneous urticaria. The main question it aims to answer is the efficacy and safety of histamine human immunoglobulin (ShuYangMinNing) in the treatment of chronic spontaneous urticaria.

Phase:

PHASE4

Details

Lead Sponsor:

Hangzhou Grand Biologic Pharmaceutical, Inc.

Treatments:

Loratadine